Saltar al contenido
Merck
Todas las fotos(1)

Documentos

1362103

USP

Levofloxacin

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

Levofloxacin hemihydrate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C18H20FN3O4 · 0.5H2O
Número de CAS:
138199-71-0
Peso molecular:
370.38
MDL number:
MFCD07772024
UNSPSC Code:
41116107
PubChem Substance ID:
329750045
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

levofloxacin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O.C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(O)=O.C[C@H]5COc6c(N7CCN(C)CC7)c(F)cc8C(=O)C(=CN5c68)C(O)=O

InChI

1S/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1

InChI key

SUIQUYDRLGGZOL-RCWTXCDDSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Application

Levofloxacin USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Levofloxacin Tablets
  • Levofloxacin Oral Solution

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Referencia del producto
Descripción
Precios

1362114

Levofloxacin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1362125

Levofloxacin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1362136

Levofloxacin Related Compound C, United States Pharmacopeia (USP) Reference Standard

1362169

Levofloxacin Related Compound F, United States Pharmacopeia (USP) Reference Standard

1362158

Levofloxacin Related Compound E, United States Pharmacopeia (USP) Reference Standard

Y0002085

Levofloxacin hemihydrate, European Pharmacopoeia (EP) Reference Standard

Y0002084

Levofloxacin impurity F, European Pharmacopoeia (EP) Reference Standard

Y0002089

Levofloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR2229

Levofloxacin Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2230

Levofloxacin Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Resp. Sens. 1 - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

R Davis et al.
Drugs, 47(4), 677-700 (1994-04-01)
Levofloxacin, an oral fluoroquinolone antibacterial agent, is the optical S-(-) isomer of ofloxacin. In vitro it is generally twice as potent as ofloxacin. Levofloxacin is active against most aerobic Gram-positive and Gram-negative organisms and demonstrates moderate activity against anaerobes. Drug
Analysis and Standardization of Levofloxacin Substance.
Sedova, M. K., et al.
Pharmaceutical Chemistry Journal, 47.11, 620-626 (2014)
Sabine Schuster et al.
Antimicrobial agents and chemotherapy, 58(11), 6870-6878 (2014-09-04)
Efflux is an important mechanism of bacterial multidrug resistance (MDR), and the inhibition of MDR pumps by efflux pump inhibitors (EPIs) could be a promising strategy to overcome MDR. 1-(1-Naphthylmethyl)-piperazine (NMP) and phenylalanine-arginine-β-naphthylamide (PAβN) are model EPIs with activity in
Lixian He et al.
Anti-cancer drugs, 26(3), 359-362 (2014-12-09)
This pilot study assesses the safety and efficacy of once-daily, oral levofloxacin monotherapy in Chinese patients with low-risk febrile neutropenia. In this prospective, single-arm, open-label, multicenter clinical trial, 46 adult Chinese patients with solid tumors and low-risk febrile neutropenia were
Kyung Eun Han et al.
American journal of ophthalmology, 157(6), 1144-1150 (2014-02-25)
To evaluate dry eye and meibomian gland dysfunction after cataract surgery. Prospective observational case series. We studied 58 eyes of 48 patients who underwent phacoemulsification and evaluated them preoperatively and at 1 month and 3 months postoperatively. Ocular symptom scores
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico